Clinical-Stage Products Focused on Novel Targets
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with large unmet medical need. By leveraging pathways absent or minimally expressed in normal cells or tissue, we aim to inhibit cancer cell growth while reducing potential harm to healthy cells. We are pursuing trials in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, and Ewing sarcoma. Looking forward, we intend to rapidly broaden our pipeline and invest in the development of our innovative therapies across multiple cancers.
We are enrolling patients:
- With B-Cell Lymphoid Malignancies (chronic lymphocytic leukemia and mantle cell lymphoma) for a Phase 1b/2 study of cirmtuzumab in combination with ibrutinib
- With HER2 negative, metastatic breast cancer for a Phase 1b study of cirmtuzumab in combination with paclitaxel
- With relapsed/refractory CLL for a Phase 2 clinical study of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor
- With Ewing sarcoma for a Phase 1 study of TK216, our small-molecule inhibitor of ETS-family transcription factor oncoproteins, in combination with vincristine